L. Hu, A. Napoletano, M. Provenzano, C. Garofalo, C. Bini, G. Comai, G. La Manna, Mineral bone disorders in kidney disease patients: the ever-current topic. Int. J. Mol. Sci. 23, 12223 (2022). https://doi.org/10.3390/ijms232012223

Article  CAS  PubMed  PubMed Central  Google Scholar 

E. Habas Sr., M. Eledrisi, F. Khan, A.Y. Elzouki, Secondary hyperparathyroidism in chronic kidney disease: pathophysiology and management. Cureus 13, e16388 (2021). https://doi.org/10.7759/cureus.16388.

Article  PubMed  PubMed Central  Google Scholar 

P. Nain, N. Nayak, M.C. Maj, R.K. Singh, J. Kaur, Y. Jeong, S. Maity, R. Nath, R.H. Hilgers, S. Nauhria, S. Nauhria, Efficacy of lanthanum carbonate and sevelamer carbonate as phosphate binders in chronic kidney disease-a comparative clinical study. Pharmacy 11, 27 (2023). https://doi.org/10.3390/pharmacy11010027

Article  PubMed  PubMed Central  Google Scholar 

S.M. Ott, Pharmacology of bisphosphonates in patients with chronic kidney disease. Semin. Dial. 28, 363–369 (2015). https://doi.org/10.1111/sdi.12388

Article  PubMed  Google Scholar 

D.E. Robinson, M.S. Ali, N. Pallares, C. Tebé, L. Elhussein, B. Abrahamsen, N.K. Arden, Y. Ben-Shlomo, F.J. Caskey, C. Cooper, D. Dedman, A. Delmestri, A. Judge, M.J. Pérez-Sáez, J. Pascual, X. Nogues, A. Diez-Perez, V.Y. Strauss, M.K. Javaid, D. Prieto-Alhambra, Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis. J. Bone Miner. Res. 36, 820–832 (2021). https://doi.org/10.1002/jbmr.4235

Article  CAS  PubMed  Google Scholar 

S.T. Bird, E.R. Smith, K. Gelperin, T.H. Jung, A. Thompson, R. Kambhampati, H. Lyu, H. Zhao, Y. Zhao, Y. Zhu, O. Easley, A. Niak, M. Wernecke, Y. Chillarige, M. Zemskova, J.A. Kelman, D.J. Graham, Severe hypocalcemia with denosumab among older female dialysis-dependent patients. Jama 331, 491–499 (2024). https://doi.org/10.1001/jama.2023.28239

Article  CAS  PubMed  PubMed Central  Google Scholar 

C.Y. Hsu, L.R. Chen, K.H. Chen, Osteoporosis in patients with chronic kidney diseases: a systemic review. Int. J. Mol. Sci. 21, 6846 (2020). https://doi.org/10.3390/ijms21186846

Article  CAS  PubMed  PubMed Central  Google Scholar 

M. Zaimi, E. Grapsa, Current therapeutic approach of chronic kidney disease-mineral and bone disorder. Ther. Apher. Dial. 28, 671–689 (2024). https://doi.org/10.1111/1744-9987.14177

Article  CAS  PubMed  Google Scholar 

J.O. Burton, D.J. Goldsmith, N. Ruddock, R. Shroff, M. Wan, Renal association commentary on the KDIGO (2017) clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. BMC Nephrol. 19, 240 (2018). https://doi.org/10.1186/s12882-018-1037-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

K. Wesseling-Perry, I.B. Salusky, Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children. Pediatr. Nephrol. 28, 617–625 (2013). https://doi.org/10.1007/s00467-012-2381-8

Article  PubMed  PubMed Central  Google Scholar 

Y.C. Hou, C.L. Lu, K.C. Lu, Mineral bone disorders in chronic kidney disease. Nephrology 23, 88–94 (2018). https://doi.org/10.1111/nep.13457

Article  CAS  PubMed  Google Scholar 

J.M. Frazão, T. Adragão, Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects. Nephron Clin. Pract. 120, c108–c119 (2012). https://doi.org/10.1159/000337087

Article  CAS  PubMed  Google Scholar 

E. Slatopolsky, H. Liapis, J. Finch, Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int. 68, 2809–2813 (2005). https://doi.org/10.1111/j.1523-1755.2005.00753.x

Article  CAS  PubMed  Google Scholar 

S. Chan, K. Au, R.S. Francis, D.W. Mudge, D.W. Johnson, P.I. Pillans, Phosphate binders in patients with chronic kidney disease. Aust. Prescr. 40, 10–14 (2017). https://doi.org/10.18773/austprescr.2017.002

Article  PubMed  PubMed Central  Google Scholar 

A. Gupta, Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity. Pharmaceuticals 7, 990–998 (2014). https://doi.org/10.3390/ph7100990

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Spaia, Phosphate binders: sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure. Hippokratia 15, 22–26 (2011)

CAS  PubMed  PubMed Central  Google Scholar 

K. Katsumata, K. Kusano, M. Hirata, K. Tsunemi, N. Nagano, S.K. Burke, N. Fukushima, Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int. 64, 441–450 (2003). https://doi.org/10.1046/j.1523-1755.2003.00126.x

Article  CAS  PubMed  Google Scholar 

C. Wang, X. Liu, Y. Zhou, S. Li, Y. Chen, Y. Wang, T. Lou, New conclusions regarding comparison of sevelamer and calcium-based phosphate binders in coronary-artery calcification for dialysis patients: a meta-analysis of randomized controlled trials. PLoS One 10, e0133938 (2015). https://doi.org/10.1371/journal.pone.0133938

Article  CAS  PubMed  PubMed Central  Google Scholar 

Q. Zeng, Y. Zhong, X. Yu, Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients. Ren. Fail. 45, 2210230 (2023). https://doi.org/10.1080/0886022x.2023.2210230

Article  CAS  PubMed  PubMed Central  Google Scholar 

A.B. Pai, B.M. Shepler, Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy 29, 554–561 (2009). https://doi.org/10.1592/phco.29.5.554

Article  CAS  PubMed  Google Scholar 

E. Gonzalez, J. Schomberg, N. Amin, I.B. Salusky, J. Zaritsky, Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients. Pediatr. Nephrol 25, 373–375 (2010). https://doi.org/10.1007/s00467-009-1328-1

Article  PubMed  PubMed Central  Google Scholar 

M. Cozzolino, M.A. Rizzo, A. Stucchi, D. Cusi, M. Gallieni, Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. Ther. Adv. Chronic Dis. 3, 59–68 (2012). https://doi.org/10.1177/2040622311433771

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Fan, C. Ross, S. Mitra, P. Kalra, J. Heaton, J. Hunter, M. Plone, N. Pritchard, A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol. Dial. Transplant. 24, 3794–3799 (2009). https://doi.org/10.1093/ndt/gfp372

Article  CAS  PubMed  PubMed Central  Google Scholar 

J. Jokihaara, I.H. Pörsti, H. Sievänen, P. Kööbi, P. Kannus, O. Niemelä, R.T. Turner, U.T. Iwaniec, T.L. Järvinen, Phosphate binding with sevelamer preserves mechanical competence of bone despite acidosis in advanced experimental renal insufficiency. PLoS One 11, e0163022 (2016). https://doi.org/10.1371/journal.pone.0163022

Article  CAS  PubMed  PubMed Central  Google Scholar 

W. Chen, H.F. Liu, Q.K. Chen, M.H. Zhao, X.N. Chen, H. Liu, J.X. Wan, S.M. Li, M.H. Chen, C. Dai, H.B. Shi, J.L. Wei, H.W. Zhao, L.H. Wang, G. Long, W.H. Lu, Y. Tang, J.W. Yang, L.Y. Cao, D.X. Tang, Y.Q. Yang, X.Q. Yu, Efficacy and safety of sevelamer carbonate in chinese nondialysis chronic kidney disease patients with hyperphosphatemia: a randomized, double-blind, parallel-group study. Kidney Dis. 9, 82–93 (2023). https://doi.org/10.1159/000527833

Article  Google Scholar 

E. Neven, B. Opdebeeck, A. De Maré, R. Bashir-Dar, G. Dams, R. Marynissen, G.J. Behets, A. Verhulst, B.L. Riser, P.C. D’Haese, Can intestinal phosphate binding or inhibition of hydroxyapatite growth in the vascular wall halt the progression of established aortic calcification in chronic kidney disease? Calcif. Tissue Int. 99, 525–534 (2016). https://doi.org/10.1007/s00223-016-0178-7

Article  CAS  PubMed